Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

malate/sarcoma

Link salvestatakse lõikelauale
Leht 1 alates 29 tulemused

Response to sunitinib malate in advanced alveolar soft part sarcoma.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma. ASPS harbors the t(17-X) (p11.2;q25) translocation, resulting in the ASPACR1-TFE3 fusion protein, causing MET autophosphorylation and activation of downstream signaling. The tumor vascular pattern prompted us
Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (i.e., imatinib

Tumor response to sunitinib malate observed in clear-cell sarcoma.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse

Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
To elucidate the origin of increased concentrations of alpha-ketoglutarate (KG) in tumor bearers the tissue distribution of KG together with the related metabolites citrate, succinate, malate, and glutamate was determined in tumor, liver, gastrocnemius muscle, and blood of rats bearing the solid

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a

Reduction of cisplatin toxicity and lethality by sodium malate in mice.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The effects of oral treatment with sodium malate, an active ingredient of Juzen-taiho-to, on the nephrotoxicity, bone marrow toxicity, hepatotoxicity and gastrointestinal toxicity caused by i.p. administration of 9 doses of 3.0 mg/kg/d cisplatin (CDDP) (on days 3, 4, 5, 6, 7, 8, 10, 11 and 12) were
The effects of ingredients of Shi-Quan-Da-Bu-Tang (Juzen-taiho-to) on the nephrotoxicity and bone marrow toxicity caused by i.p. administration of 3 mg/kg cis-diamminedichloroplatinum (II) (CDDP) 9 times (on days 3, 4, 5, 6, 7, 8, 10, 11, 12) were examined in ddY mice s.c. inoculated with sarcoma

Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A gastrointestinal stromal tumor (GIST) is a soft tissue sarcoma that can occur anywhere along the gastrointestinal (GI) tract and is the most common noncarcinomatous malignancy of the GI tract. This article will review the pathology of GISTs, the molecular pathology related to c-kit, and disease
1. When a malignant growth is developing in a patient, one often observes in the serum an increased activity of serum enzymes due to necrosis and increased membrane permeability caused by the altered metabolism of malignant cells. Conversely, I considered it interesting to check the enzymes of the

Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Antiangiogenic treatment activity has been reported in solitary fibrous tumor (SFT), a rare and little chemosensitive sarcoma. We explored the activity of sunitinib malate (SM) in SFT and studied receptor tyrosine kinase (RTK) activation profile. Eleven patients with progressive metastatic SFT
BACKGROUND Soft tissue sarcomas are a heterogeneous group of malignant neoplasms including several distinct entities with different cell differentiation and clinical prognosis, but which are often treated as a single disease. METHODS We report the case of a male patient, heavily treated for a
Sunitinib, an oral tyrosine kinase inhibitor, has been approved by the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma and imatinib-refractory gastrointestinal stromal tumor. In non-gastrointestinal stromal tumor soft tissue sarcomas, the activity of this

Electrophoretic investigation of some dehydrogenases in Leishmania amastigotes.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Amastigotes of Leishmania mexicana mexicana and of Leishmania donovani were grown in mouse peritoneal macrophages and dog sarcoma cells in culture. Polyacrylamide gel disc electrophoresis of amastigote-infected tissue cultures failed to detect parasite lactate dehydrogenase and malate dehydrogenase,

Molecular response prediction in gastrointestinal stromal tumors.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Gastrointestinal stromal tumors (GISTs) are rare tumors of mesenchymal origin that develop along the gastrointestinal tract. Over ten years ago, their management dramatically changed following the discovery of an activating mutation of the KIT oncogene, which led to the use of small molecule
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge